Pular para o conteúdo
Neurofibromatose tipo 1
ORPHA:636CID-10 · Q85.0CID-11 · LD2D.10OMIM 162200DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
neuroInício neonatalHerança AD
Também conhecida comoDoença de von RecklinghausenDoença von RecklinghausenNeurofibromatose não em mosaicoNF 1NF1
Sinônimos clínicos: Doença von Recklinghausen · NF 1 não em mosaico · Neurofibromatose não em mosaico

Doença genética neurocutânea, clinicamente heterogênea, caracterizada por manchas café com leite, nódulos de Lisch na íris, sardas axilares e inguinais e múltiplos neurofibromas.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A neurofibromatose tipo 1 é uma condição caracterizada por alterações na coloração da pele (pigmentação) e pelo crescimento de tumores ao longo dos nervos na pele, no cérebro e em outras partes do corpo. Os sinais e sintomas dessa condição variam amplamente entre as pessoas com a condição.

A partir da primeira infância, quase todas as pessoas com neurofibromatose tipo 1 apresentam múltiplas manchas café-au-lait, que são áreas planas na pele mais escuras que a região circundante. Essas manchas aumentam de tamanho e número à medida que o indivíduo envelhece. Sardas nas axilas e na região da virilha geralmente se desenvolvem mais tarde na infância.

A maioria dos adultos com neurofibromatose tipo 1 desenvolve neurofibromas, que são tumores não cancerosos (benignos) que geralmente se localizam na superfície da pele ou logo abaixo dela. Esses tumores também podem ocorrer em nervos próximos à medula espinhal ou ao longo de nervos em outras partes do corpo. Algumas pessoas com neurofibromatose tipo 1 desenvolvem tumores cancerosos que crescem ao longo dos nervos. Esses tumores, que geralmente se desenvolvem na adolescência ou na idade adulta, são chamados de tumores malignos da bainha do nervo periférico. Pessoas com neurofibromatose tipo 1 também apresentam risco aumentado de desenvolver outros tipos de câncer, incluindo tumores cerebrais e câncer do tecido formador de sangue (leucemia).

Durante a infância, crescimentos benignos chamados nódulos de Lisch frequentemente aparecem na parte colorida do olho (a íris). Os nódulos de Lisch não interferem na visão. Algumas pessoas com a condição também desenvolvem tumores que crescem ao longo do nervo que liga o olho ao cérebro (o nervo óptico). Esses tumores, que são chamados de gliomas ópticos, podem levar à redução da visão ou à perda total da visão. Em alguns casos, os gliomas ópticos não têm efeito sobre a visão.

Sinais e sintomas adicionais da neurofibromatose tipo 1 variam, mas podem incluir pressão arterial alta (hipertensão), baixa estatura, cabeça incomumente grande (macrocefalia) e anomalias esqueléticas, como curvatura anormal da coluna (escoliose). Embora a maioria das pessoas com neurofibromatose tipo 1 tenha inteligência normal, dificuldades de aprendizagem e transtorno de déficit de atenção/hiperatividade (TDAH) ocorrem com frequência em indivíduos com a condição.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

Doença genética neurocutânea, clinicamente heterogênea, caracterizada por manchas café com leite, nódulos de Lisch na íris, sardas axilares e inguinais e múltiplos neurofibromas.

Pesquisas ativas
35 ensaios
128 total registrados no ClinicalTrials.gov
Publicações científicas
7.666 artigos
Último publicado: 2026 Apr 16
Medicamentos
2 com registro
Gomekli (MIRDAMETINIB), KOSELUGO (SELUMETINIB)

Tem tratamento?

✓ 2 medicamentos específicos desta doença (registro ANVISA, FDA ou SUS/CEAF)
Ver detalhes, fases e interações →
GOMEKLI (MIRDAMETINIB)KOSELUGO (SELUMETINIB)

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
21.0
United Kingdom
Início
Infancy
+ neonatal
🏥
SUS: Cobertura mínimaScore: 15%
5 procedimentos SIGTAPCID-10: Q85.0
🇧🇷Dados SUS / DATASUS
EXAMES E PROCEDIMENTOS RELACIONADOS (5)
•
Cariótipo — bandas G, Q ou R
•
Pesquisa de microdeleções/microduplicações por FISH
•
Sequenciamento completo do exoma (WES)
•
Dosagem de alfa-fetoproteína
•
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
30 sintomas
🦴
Ossos e articulações
29 sintomas
👁️
Olhos
18 sintomas
😀
Face
17 sintomas
❤️
Coração
14 sintomas
🧬
Pele e cabelo
10 sintomas

+ 84 sintomas em outras categorias

Características mais comuns

100%prev.
Glioma
Frequência: 2/2
100%prev.
Feocromocitoma
Ocasional (29-5%)
90%prev.
Mácula
Muito frequente (99-80%)
90%prev.
Nevo melanocítico
Muito frequente (99-80%)
90%prev.
Meningioma
Muito frequente (99-80%)
90%prev.
Nódulo subcutâneo
Muito frequente (99-80%)
233sintomas
Muito frequente (15)
Frequente (25)
Ocasional (42)
Muito raro (22)
Sem dados (129)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 233 características clínicas mais associadas, ordenadas por frequência.

Frequência: 2/2100%
FeocromocitomaPheochromocytoma
Ocasional (29-5%)100%
MáculaMacule
Muito frequente (99-80%)90%
Nevo melanocíticoMelanocytic nevus
Muito frequente (99-80%)90%
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico7.666PubMed
Últimos 10 anos200publicações
Pico2026141 papers
Linha do tempo
2026Hoje · 2026🧪 1999Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

Curadoria gene-doença

fontes oficiais
NF1
NF1
PanelApp · Segmental or atypical neurofibromatosis type 1 testingGenomics England
NF1
NF1NeurofibrominDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
RAS signaling downstream of NF1 loss-of-function variants
MECANISMO DE DOENÇA

Neurofibromatosis 1

A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
17.9 TPM
Cérebro - Hemisfério cerebelar
17.1 TPM
Cerebelo
15.3 TPM
Nervo tibial
14.9 TPM
Tireoide
14.1 TPM
OUTRAS DOENÇAS (12)
neurofibromatosis, familial spinalneurofibromatosis type 1juvenile myelomonocytic leukemiaWatson syndrome
HGNC:7765UniProt:P21359
RNF135E3 ubiquitin-protein ligase RNF135Candidate gene tested inTolerante
VIAS BIOLÓGICAS (8)
DDX58/IFIH1-mediated induction of interferon-alpha/betaSARS-CoV-2 activates/modulates innate and adaptive immune responsesNegative regulators of DDX58/IFIH1 signalingTRAF3-dependent IRF activation pathwayOvarian tumor domain proteases
EXPRESSÃO TECIDUAL(Ubíquo)
Baço
28.9 TPM
Skin Sun Exposed Lower leg
27.5 TPM
Skin Not Sun Exposed Suprapubic
26.2 TPM
Tecido adiposo
23.9 TPM
Cervix Endocervix
22.4 TPM
OUTRAS DOENÇAS (1)
chromosome 17q11.2 deletion syndrome, 1.4Mb
HGNC:21158UniProt:Q8IUD6

Medicamentos aprovados (FDA)

2 medicamentos encontrados nos registros da FDA americana.

💊 Gomekli (MIRDAMETINIB)
💊 KOSELUGO (SELUMETINIB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

7.251 variantes patogênicas registradas no ClinVar.

🧬 NF1: NM_001042492.3(NF1):c.1932del (p.Met645fs) ()
🧬 NF1: NM_001042492.3(NF1):c.388C>A (p.His130Asn) ()
🧬 NF1: NM_001042492.3(NF1):c.1541dup (p.Pro516fs) ()
🧬 NF1: NM_001042492.3(NF1):c.5533A>G (p.Ile1845Val) ()
🧬 NF1: NM_001042492.3(NF1):c.2895A>G (p.Ile965Met) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 13.834 variantes classificadas pelo ClinVar.

2767
6917
4150
Patogênica (20.0%)
VUS (50.0%)
Benigna (30.0%)
VARIANTES MAIS SIGNIFICATIVAS
NF1: NM_001042492.3(NF1):c.6904_6916del (p.Gln2302fs) [Pathogenic]
ADAP2: Single allele [Likely pathogenic]
NF1: NM_001042492.3(NF1):c.1932del (p.Met645fs) [Pathogenic]
NF1: NM_001042492.3(NF1):c.1541dup (p.Pro516fs) [Pathogenic]
NF1: NM_001042492.3(NF1):c.388C>A (p.His130Asn) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado1
3Fase 32
2Fase 226
1Fase 117
·Pré-clínico54
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 100 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neurofibromatose tipo 1

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 8 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

17 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT06507748 · A Study to Evaluate the Feasibility of a Physiologic Biomark…Recrutando
NA🇺🇸 Estados Unidos
NCT07102394 · Feasibility and Tolerability of IMLYGIC for the Treatment of…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07233408 · Tailoring an Online Platform to Promote Evidence-Based Care …Recrutando
NA🇺🇸 Estados Unidos
NCT07221331 · Prevalence, Clinical Characteristics, Progression, and Manag…Recrutando
🇪🇬 Egito
NCT07237100 · Mirdametinib in Patients With Advanced NF1-mutant MelanomaRecrutando
PHASE2🇺🇸 Estados Unidos
NCT07088991 · Clinical and Demographic Characteristics of Adult p Atients …Recrutando
Russia
NCT06961565 · PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Ple…Recrutando
PHASE1🇦🇺 Austrália · South Korea · 🇺🇸 Estados Unidos
NCT06880991 · Development of Patient-Reported Outcome Measures Assessing T…Recrutando
🇺🇸 Estados Unidos
NCT06541847 · A Phase 2, Open-Label Study to Evaluate the Safety and Effec…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06147414 · Development of Non-Invasive Prenatal Diagnosis for Single Ge…Recrutando
🇫🇷 França
NCT05489783 · Glioma Developmental and HyperActive Ras Tumor (DHART) BoardRecrutando
🇺🇸 Estados Unidos
NCT04763109 · Identification of Pre-Malignant Lesions In Pediatric Patient…Recrutando
NA🇺🇸 Estados Unidos
NCT05954416 · FARD (RaDiCo Cohort) (RaDiCo-FARD)Recrutando
🇫🇷 França
NCT01885767 · Neurofibromatosis (NF) Registry PortalRecrutando
🇺🇸 Estados Unidos
NCT00598351 · Natural History Study of Patients With Neurofibromatosis Typ…Recrutando
🇺🇸 Estados Unidos
NCT06515860 · Neurofibromatosis Type 1 Tumor Early Detection StudyPor convite
🇺🇸 Estados Unidos
NCT05238909 · Developing Biomarkers of Plexiform Tumor Burden in Patients …Por convite
🇺🇸 Estados Unidos

Outros ensaios clínicos

128 ensaios clínicos encontrados, 35 ativos.

Distribuição por fase
NCT07850635 · A Study of Mirdametinib in Infants and Toddlers With Neurofi…Em breve
PHASE1🇩🇪 Alemanha
NCT07843823 · Neurocutaneous Syndromes in Children: Prevalence and Clinica…Em breve
NCT07818213 · How Can the Experience of Hospital Outpatient Departments be…Em breve
🇬🇧 Reino Unido
NCT07564622 · Gait in Young Children With NF1Em breve
NCT03359304 · The Neurofibromatosis-associated Tumor BiobankEm breve
NCT05388370 · PASS of Paediatric Patients Initiating SelumetinibAtivo
🇦🇹 Áustria · 🇫🇷 França · 🇩🇪 Alemanha +7
NCT05309668 · Pharmacokinetics, Safety and Efficacy of the Selumetinib Gra…Ativo
PHASE1, PHASE2🇩🇪 Alemanha · 🇮🇹 Itália · 🇯🇵 Japão +4
NCT05101148 · Phase I Study to Assess the Effect of Food on the PK and Gas…Ativo
PHASE1🇵🇱 Polônia · Russia · 🇪🇸 Espanha +1
NCT05581511 · Natural History Study of Cutaneous Neurofibromas in People W…Ativo
🇺🇸 Estados Unidos
NCT04201457 · A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03871257 · A Study of the Drugs Selumetinib Versus Carboplatin/Vincrist…Ativo
PHASE3🇨🇦 Canadá · Puerto Rico · 🇺🇸 Estados Unidos
NCT03962543 · MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neu…Ativo
PHASE2🇺🇸 Estados Unidos
NCT03190915 · Trametinib in Treating Patients With Relapsed or Refractory …Ativo
PHASE2🇺🇸 Estados Unidos
NCT03820778 · Whole Body MRI to Identify Atypical Neurofibromas in Patient…Ativo
NA🇺🇸 Estados Unidos
NCT02964884 · Interventions for Reading Disabilities in NF1Ativo
PHASE2🇺🇸 Estados Unidos
NCT01362803 · AZD6244 Hydrogen Sulfate for Children With Nervous System Tu…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01089101 · Selumetinib in Treating Young Patients With Recurrent or Ref…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00924196 · Natural History Study of Patients With Neurofibromatosis Typ…Ativo
🇺🇸 Estados Unidos
NCT06262113 · A Decentralized Clinical Trial to Promote Evidence-Based Car…Concluído
NA🇺🇸 Estados Unidos
NCT05438290 · DPCP to Treat Cutaneous Neurofibromas Associated With NF1Concluído
PHASE1🇺🇸 Estados Unidos
NCT05196854 · Clinical Hypnosis and Home Blood Pressure Monitoring in Chil…Concluído
NA🇦🇺 Austrália
NCT05377008 · Intervention Effectiveness on the Neurocognitive Functioning…Concluído
NA🇺🇸 Estados Unidos
NCT05149469 · Molecular Aspects of Preimplantation Genetic Diagnosis for N…Concluído
🇫🇷 França
NCT04495127 · Selumetinib Paediatric NF1 Japan StudyConcluído
PHASE1🇯🇵 Japão
NCT04153344 · Function of the Pigment Epithelium in Patients With Type 1 N…Concluído
🇫🇷 França
NCT03326388 · Intermittent Dosing Of Selumetinib In Childhood NF1 Associat…Concluído
PHASE1, PHASE2🇬🇧 Reino Unido
NCT03888248 · Whole-body Vibration in Children With Neurofibromatosis Type…Concluído
NA🇬🇧 Reino Unido
NCT04212351 · Frameshift Peptides of Children With NF1Concluído
🇺🇸 Estados Unidos
NCT03649165 · A Study to Evaluate Bioavailability and Food Effect of Selum…Concluído
PHASE1🇺🇸 Estados Unidos
NCT03231306 · Phase II Study of Binimetinib in Children and Adults With NF…Concluído
PHASE2🇺🇸 Estados Unidos
NCT03406208 · Resiliency Training for Adults With Neurofibromatosis Via Li…Concluído
NA🇺🇸 Estados Unidos
NCT02839720 · Selumetinib in Treating Patients With Neurofibromatosis Type…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02700230 · Vaccine Therapy in Treating Patients with Malignant Peripher…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02777775 · Targeting the Mechanisms Underlying Cutaneous Neurofibroma F…Concluído
🇺🇸 Estados Unidos
NCT02944032 · Efficacy of Computerized Cognitive Training and Stimulant Me…Concluído
NA🇺🇸 Estados Unidos
NCT02415153 · Pomalidomide in Treating Younger Patients With Recurrent, Pr…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02471339 · Acceptance and Commitment Training for Adolescents and Young…Concluído
PHASE3🇺🇸 Estados Unidos
NCT02435628 · Relationship Between Psychosocial Factors, Health Literacy, …Concluído
🇺🇸 Estados Unidos
NCT02387177 · Resiliency Training for Adolescent Neurofibromatosis Patient…Concluído
NA🇺🇸 Estados Unidos
NCT02211768 · Transformation of Plexiform Neurofibromas to Malignant Perip…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02101736 · Cabozantinib for Plexiform Neurofibromas (PN) in Subjects Wi…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02096471 · MEK Inhibitor PD-0325901 Trial in Adolescents and Adults Wit…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02298270 · Resiliency Training for Patients With Neurofibromatosis Via …Concluído
NA🇺🇸 Estados Unidos
NCT01851135 · Neuropsychological Impairment and Quality of Life in Neurofi…Concluído
NA🇫🇷 França
NCT01707836 · Neurofibromatosis Type 1 Brain Tumor Genetic RiskConcluído
🇺🇸 Estados Unidos
NCT01639950 · Validating Pain Scales in Children and Young AdultsConcluído
🇺🇸 Estados Unidos
NCT01553149 · Low-Dose or High-Dose Lenalidomide in Treating Younger Patie…Concluído
PHASE2🇦🇺 Austrália · 🇨🇦 Canadá · New Zealand +1
NCT01633008 · Acceptance and Commitment Therapy for Adolescents and Young …Concluído
EARLY_PHASE1🇺🇸 Estados Unidos
NCT01140360 · Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 71605…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01595139 · MicroRNAs in Patients With Neurofibromatosis Type 1Concluído
🇺🇸 Estados Unidos
NCT01410006 · Neurofibromatosis Type 1 Patient RegistryConcluído
🇺🇸 Estados Unidos
NCT01412892 · Use of RAD001 as Monotherapy in the Treatment of Neurofibrom…Concluído
PHASE2🇫🇷 França
NCT01275586 · Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (N…Concluído
EARLY_PHASE1🇺🇸 Estados Unidos
NCT01222728 · Using Positron Emission Tomography to Predict Intracranial T…Concluído
🇺🇸 Estados Unidos
NCT01125046 · Bevacizumab in Treating Patients With Recurrent or Progressi…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01058330 · Effects of Physical Training on Bone and Muscle Quality, Mus…Concluído
NA🇺🇸 Estados Unidos
NCT01031901 · Topical Rapamycin Therapy to Alleviate Cutaneous Manifestati…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00853580 · A Randomized Placebo-Controlled Study of Lovastatin in Child…Concluído
PHASE2🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT02397967 · Reading Disability in Children With NF1Concluído
NA🇫🇷 França
NCT02422732 · Functional Imaging and Reading Deficit in Children With NF1Concluído
NA🇫🇷 França
NCT00865644 · Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurof…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00824278 · The Use of a Distress Thermometer in a Pediatric Research Se…Concluído
🇺🇸 Estados Unidos
NCT00684398 · Adaptation and Quality of Life Among Adults With Neurofibrom…Concluído
🇺🇸 Estados Unidos
NCT00634270 · A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofib…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00657202 · Ranibizumab for Neurofibromas Associated With Neurofibromato…Concluído
EARLY_PHASE1🇺🇸 Estados Unidos
NCT00589784 · Phase II Trial of Sunitinib (SU011248) in Patients With Recu…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01445314 · Analysis of Data Collected From Individuals Administered Neu…Concluído
🇺🇸 Estados Unidos
NCT00844129 · Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)Concluído
🇺🇸 Estados Unidos
NCT00314119 · Natural History and Biology of Skin Neurofibromas in Neurofi…Concluído
🇺🇸 Estados Unidos
NCT00352495 · Vinblastine and Carboplatin in Treating Young Patients With …Concluído
PHASE1🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT01673009 · Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 71…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00667836 · Multi-center Project: Spinal Abnormalities in Neurofibromato…Concluído
🇺🇸 Estados Unidos
NCT00624234 · Neurobiology and Treatment of Reading Disability in NF-1Concluído
NA🇺🇸 Estados Unidos
NCT00304083 · Combination Chemotherapy in Treating Patients With Stage III…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00111384 · Study of Disease Severity in Adults With Neurofibromatosis T…Concluído
🇺🇸 Estados Unidos
NCT00508235 · Quality of Friendships in Children With NeurofibromatosisConcluído
🇺🇸 Estados Unidos
NCT00303368 · Neurofibromatosis Type 1 (NF1) and Tibial DysplasiaConcluído
🇺🇸 Estados Unidos
NCT00169611 · NF1-Attention: Study of Children With Neurofibromatosis Type…Concluído
PHASE4🇫🇷 França
NCT00053937 · Pirfenidone in Treating Young Patients With Neurofibromatosi…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00026780 · Eligibility Screening for a NCI Pediatric Oncology Branch Re…Concluído
🇺🇸 Estados Unidos
NCT00021541 · R115777 to Treat Children With Neurofibromatosis Type 1 and …Concluído
PHASE2🇩🇪 Alemanha · 🇺🇸 Estados Unidos
NCT00030264 · Combination Chemotherapy in Treating Patients With Neurofibr…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00754780 · Clinical Trial of Pirfenidone in Adult Patients With Neurofi…Concluído
PHASE2
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
4.292 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 4.292

#1

Utility of 18F-FDG PET/CT in the Surveillance of Patients With Neurofibromatosis Type 1.

Neurology. Genetics2026 Apr

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that predisposes affected individuals to benign and malignant tumors throughout their lifetime. Early detection of those lesions is critical for effective management. PET/CT with 18F-fluorodeoxyglucose (18F-FDG) has emerged as a potentially efficient modality for detecting malignant tumors in patients with NF1. The aim of this study was to investigate this hypothesis by assessing the presence of incidental findings of malignant and potentially malignant tumors using 18F-FDG PET/CT in an adult NF1 cohort. In this retrospective observational study, clinical data were collected from medical records, including sex, age, family history, clinical manifestations, and tumor diagnosis. Data on imaging and diagnostic modalities that led to the diagnosis of NF1-related tumors or other malignant and potentially malignant tumors were collected. These modalities included 18F-FDG PET/CT, MRI, CT, mammography, scintigraphy, and pathology reports. A total of 79 adult patients with NF1 were included in this study, comprising 29 male and 50 female patients, all of whom had received an NF1 diagnosis. Of these, 51 patients (64.6%) underwent a 18F-FDG PET/CT scan during their follow-up. A total of 31 malignant or potentially malignant tumors were diagnosed in addition to 2 pheochromocytomas and 24 gliomas. Notably, 18F-FDG PET/CT scans incidentally detected 12 significant findings: 4 gastrointestinal stromal tumors, 3 carcinomas and premalignant tumors of the thyroid gland, 2 malignant peripheral nerve sheath tumors, 1 serous borderline ovarian tumor, 1 testicular seminoma, and 1 pheochromocytoma. Most incidental findings required surgery and could have significantly affected disease management if diagnosed at a later stage. In this cohort of 79 adult patients with NF1, 18F-FDG PET/CT proved as a valuable complementary imaging modality to conventional imaging by enabling the detection of incidental malignant or potentially malignant tumors. Our results highlight 18F-FDG PET/CT's beneficial impact on disease management by suggesting that the incorporation of 18F-FDG PET/CT into screening protocols could improve early detection of NF1-related cancers in asymptomatic adults, potentially offering early treatment options to improve clinical outcomes.

#2

Differences in Optic Pathway Glioma Prevalence among Children with Neurofibromatosis Type 1.

The Journal of pediatrics2026 Mar 17

This multi-institutional, natural language processing-based analysis of 273 children with neurofibromatosis 1-associated optic pathway gliomas examines the impact of ancestral background on clinical presentation and progression. We report that White children had higher OPG prevalence than Black or Asian children, but clinical features and outcomes did not differ across groups.

#3

Novel Variants in PTPN11, NF1, RASA2, and MAP2K1: Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort.

Clinical genetics2026 Mar 19

RASopathies are a group of genetically heterogeneous developmental disorders caused by germline variants affecting the RAS/MAPK signaling pathway. These disorders display overlapping clinical features and diverse molecular mechanisms. This study aimed to evaluate the clinical and molecular spectrum of patients diagnosed with RASopathies, with a particular focus on novel and rare variants. A retrospective, multicenter study was conducted on patients with clinically suspected RASopathy and diagnosed by targeted Next Generation Sequencing analysis between 2021 and 2024. Variants were classified according to ACMG criteria, and clinical data were reviewed for genotype-phenotype correlations. Among 23 patients (14 males, 9 females), 15 (65.2%) had Noonan syndrome, five (21.7%) Neurofibromatosis Type 1, two (8.7%) Cardio-facio-cutaneous syndrome, and one (4.3%) Neurofibromatosis-Noonan syndrome. The most frequent clinical findings were craniofacial dysmorphism (91.3%), musculoskeletal anomalies (82.6%), and cutaneous features (78.3%). A total of 24 heterozygous variants were identified in seven genes: PTPN11 (45.8%), NF1 (25%), LZTR1 (12.5%), and RASA2, SOS1, MAP2K1, and BRAF (each 4.2%). Four novel variants were detected (PTPN11 c.853 + 4A>G, RASA2 p.E71D, NF1 p.W784Mfs*10, MAP2K1 p.A106T). This study highlights the clinical and molecular heterogeneity of RASopathies and expands the variant spectrum with novel and rare pathogenic alterations. The identification of new variants, particularly in rarely implicated genes such as RASA2, underlines the diagnostic value of comprehensive NGS-based testing and the need for individualized, multidisciplinary clinical management.

#4

Metabolic and behavioral effects of neurofibromin result from differential recruitment of MAPK and mTOR signaling.

PLoS genetics2026 Mar

Neurofibromatosis type 1 results from mutations in the NF1 gene and its encoded neurofibromin protein. This condition produces multiple symptoms, including tumors, behavioral alterations, and metabolic changes. Molecularly, neurofibromin mutations affect Ras activity, influencing multiple downstream signaling pathways, including MAPK (Raf/MEK/ERK) and PI3K/Akt/mTOR signaling. This pleiotropy raises the question of which pathways could be targeted to treat the disease symptoms, and whether different phenotypes driven by neurofibromin mutations exhibit similar or diverging dependence on the signaling pathways downstream of Ras. To test this, we examined metabolic and behavioral alterations in the genetically tractable Drosophila neurofibromatosis type 1 model. In vivo genetic analysis revealed that behavioral effects of neurofibromin were mediated by MEK signaling, with no necessity for Akt. In contrast, metabolic effects of neurofibromin were mediated by coordinated actions MEK/ERK and Akt/mTOR/S6K/4E-BP signaling. At the systemic level, loss of neurofibromin dysregulated metabolism via molecular effects in interneurons and muscle. These changes were accompanied by altered muscle mitochondria morphology, with no concomitant changes in neuronal ultrastructure or neuronal mitochondria. Overall, this suggests that neurofibromin mutations affect multiple signaling cascades downstream of Ras, which differentially affect metabolic and behavioral neurofibromatosis type 1 phenotypes.

#5

Giant malignant peripheral nerve sheath tumor: Illustrative case and surgical technique.

Surgical neurology international2026

Malignant peripheral nerve sheath tumors (MPNSTs) are one of the most difficult malignant mesenchymal neoplasms to treat. They can arise from a preexisting peripheral nerve sheath or in neurofibromatosis type 1 (NF1) patients. MPNSTs in the head-and-neck region represent approximately 2-6% of all head-and-neck sarcomas and account for 12-19% of all MPNSTs. It has an incidence of 0.001% in the general population, and prognosis is typically poor; only between 20% and 50% of patients survive 5 years after diagnosis. The complete surgical resection is recommended whenever possible. The authors report the case of a 31-year-old woman with a history of plexiform neurofibroma, who presented with recurrence with disease progression to MPNST, without association with NF1 disease. The aim of tumor resection is symptomatic relief. These tumors have a high risk of severe complications and even mortality due to various causes. The benefits - including the emotional ones - can be so significant that, despite their malignant lineage, resection and regrowth control remain worthwhile for as long as possible. Four- or six-hand surgery for these tumors can reduce bleeding, operative time, and complications.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC4.300 artigos no totalmostrando 197

2026

Utility of 18F-FDG PET/CT in the Surveillance of Patients With Neurofibromatosis Type 1.

Neurology. Genetics
2026

Benign Peripheral Nerve Sheath Tumors: Recurrence Rates and Pain Outcomes Following Excision.

Plastic and reconstructive surgery
2026

Frontotemporal-orbitozygomatic approach for pediatric cranio-orbital tumors: a single-center experience.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

Cardiotoxicity of trametinib monotherapy in adults with neurofibromatosis type 1: Results from the TRAIN study.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2026

Differences in Optic Pathway Glioma Prevalence among Children with Neurofibromatosis Type 1.

The Journal of pediatrics
2026

Lumbar Fracture Dislocation in a 14-Year-Old with Dystrophic Scoliosis, Neurofibromatosis Type 1, and a Normal Neurologic Examination: A Case Report.

JBJS case connector
2026

Novel Variants in PTPN11, NF1, RASA2, and MAP2K1: Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort.

Clinical genetics
2026

Building a framework for adolescent and young adult transition of care for patients with neurofibromatosis type 1 and neurofibromatosis type 2-related schwannomatosis syndromes.

Frontiers in oncology
2026

Adult patient and caregiver perspectives on the impact of NF1-PN: Insights from a US qualitative survey.

Neuro-oncology advances
2026

Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis.

Neuro-oncology advances
2026

Aorto-Renal Dysplasia in Childhood: The Overlap of Neurofibromatosis Type 1 and Pediatric Renovascular Hypertension.

Current hypertension reports
2026

A rare case report of solitary neurofibroma arising in the male breast.

International journal of surgery case reports
2026

Case Report: Somatic NF2 mutation in a vestibular schwannoma arising in a patient with neurofibromatosis type 1.

Frontiers in oncology
2026

[Pheochromocytoma in Neurofibromatosis Type 1].

Problemy endokrinologii
2026

Surgical Outcomes in NF-1-Associated Upper Thoracic Dystrophic Scoliosis: A Retrospective Analysis.

World neurosurgery
2026

Trametinib and Fimepinostat Induce Malignant Peripheral Nerve Sheath Tumor Cell Death In Vitro.

Cancers
2026

EEG response to hyperventilation in patients with neurofibromatosis type 1 and Moyamoya syndrome: Two case reports.

Neurophysiologie clinique = Clinical neurophysiology
2025

Congenital Upper Extremity Anomalies Misdiagnosed as Ulnar Longitudinal Deficiency.

Eplasty
2026

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Expert review of anticancer therapy
2026

Surgical treatment of gastrointestinal stromal tumors.

Journal of medicine and life
2026

GNAQ positive hepatic vascular tumors in a patient with neurofibromatosis type 1: A case report.

JAAD case reports
2026

Translation and Cultural Adaptation of the PedsQL Neurofibromatosis Module, Version 3.0, Into Brazilian Portuguese.

Cureus
2026

Patient and caregiver perspectives on neurodevelopmental and mental health care for RASopathies.

Therapeutic advances in rare disease
2026

High-frequency ultrasound in genodermatoses.

Journal of ultrasound
2025

Pancreatic Atypical Neurofibromatous Neoplasm with Uncertain Biological Potential (ANNUBP) Mimicking a Solid Pseudopapillary Tumor Pancreatic ANNUBP.

Acta gastroenterologica Latinoamericana
2026

Neurofibromatosis type 1 with unilateral macrodactyly-like overgrowth: a case report.

Case reports in plastic surgery &amp; hand surgery
2026

Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review.

Neuro-oncology advances
2026

Pediatric high-grade gliomas in patients with neurofibromatosis type 1-A collaborative cohort study from the SIOPE HGG/DIPG working group.

Neuro-oncology practice
2026

Neurogenetic tumor syndromes: The current landscape of workup and treatment.

Neuro-oncology practice
2026

Patient and caregiver experiences with selumetinib for the treatment of pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

Neuro-oncology practice
2026

Rare Association Between Neurofibromatosis Type 1 and Adrenocortical Carcinoma.

Clinical case reports
2026

Excessive intraoperative hemorrhage during orthognathic surgery in a patient with neurofibromatosis type 1: a case report and literature review.

Oral and maxillofacial surgery
2026

Precision restoration of complex cervical instability and decompression for neurofibromatosis type I: a case report using patient-specific 3D-printed templates.

Frontiers in surgery
2026

Isolated Anterior Mesenteric Neurofibroma: A Rare Manifestation of Neurofibromatosis Type 1.

Cureus
2026

Tibial lengthening in congenital pseudoarthrosis of the tibia: a scoping review.

BMC musculoskeletal disorders
2026

Metabolic and behavioral effects of neurofibromin result from differential recruitment of MAPK and mTOR signaling.

PLoS genetics
2026

PTPN11-related Noonan syndrome predisposes to multifocal low-grade CNS tumors harboring FGFR1 variants.

Journal of neuro-oncology
2026

Giant malignant peripheral nerve sheath tumor: Illustrative case and surgical technique.

Surgical neurology international
2026

Breathless and Beyond: Anterior Mediastinal Malignant Peripheral Nerve Sheath Tumor as a Rare Neurofibromatosis Type 1 Manifestation.

Clinical case reports
2026

Retinal and Choroidal Changes in Neurofibromatosis Type 1 in Relation to Diagnostic Criteria and Disease Severity.

Current eye research
2026

Ossification of Mandibular Central Giant Cell Granuloma (CGCG) in Neurofibromatosis Type 1 Patients.

Cancer diagnosis &amp; prognosis
2026

A 17-Year-Old Male Adolescent With a Giant Isolated Scalp Neurofibroma Associated With a Calvarial Defect: A Case Report.

The American journal of case reports
2026

IFN signaling at the nexus of the radiotherapy response in malignant peripheral nerve sheath tumors.

The Journal of clinical investigation
2026

Neurofibromatosis type 1 with concomitant Peutz-Jeghers syndrome in a child: a case report.

BMC pediatrics
2026

Clinical Outcomes Following Surgical Resection for Patients With Malignant Peripheral Nerve Sheath Tumors.

Neurosurgery
2026

Duodenal ampullary neuroendocrine tumor, high risk gastrointestinal stromal tumor, and gastric leiomyoma in a patient with neurofibromatosis type 1: a rare case report and literature review.

Frontiers in oncology
2026

A Systematic Review and Meta-Analysis of Executive Function Outcomes in Pediatric Central Nervous System Tumor Survivors.

Actas espanolas de psiquiatria
2026

Neurovascular Issues in Neurofibromatosis Type I: Focus on Intracranial Stenosis.

Life (Basel, Switzerland)
2026

Cystic lung diseases in the daily routine: a comprehensive step-wise algorithm for the radiological diagnosis of cystic lung lesions and diffuse cystic lung diseases.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
2026

Bilateral pheochromocytoma as a late presentation of neurofibromatosis type 1.

Endocrinology, diabetes &amp; metabolism case reports
2026

Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L-Amino Acid Decarboxylase Deficiency Using an MR-Compatible Cannula: 48 Weeks of Follow-Up.

Journal of inherited metabolic disease
2026

Ampullary Mixed Adenoma and Well-Differentiated Neuroendocrine Tumor (MANET) with Aberrant Beta-Catenin Expression in a Patient with Neurofibromatosis Type 1.

Endocrine pathology
2026

Unusual Presentation of Plexiform Neurofibroma Embedded with Large Comedones: A Case Report.

Case reports in dermatology
2026

High-Yield DNA-Based Neurofibromatosis Type 1 Diagnostics Reveal Population-Specific Mutation Landscape in 1917 Koreans.

The Journal of molecular diagnostics : JMD
2026

Retinal Astrocytic Hamartoma in a Child With Neurofibromatosis Type 1 Treated With Selumetinib.

Pediatrics
2026

Cerebrovascular Malformations Associated With Hereditary Hemorrhagic Telangiectasia and HHT-Like Syndromes: A Comparative Overview.

European journal of neurology
2026

Cancer predisposition syndromes: an imaging review.

Cancer imaging : the official publication of the International Cancer Imaging Society
2026

End of a diagnostic odyssey: the added value of multi-tissue analysis in the identification of mosaicism in tumour predisposition syndromes.

Journal of medical genetics
2026

Intelligence Over Time in Children with Neurofibromatosis Type 1 Based on a Structured Natural History-Study.

Journal of child neurology
2026

Single-stage posterior surgical management of grade 5 L5 spondylolisthesis in a patient with neurofibromatosis type 1 and dural meningocele: illustrative case.

Journal of neurosurgery. Case lessons
2026

Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.

Spine surgery and related research
2026

Congenital pseudarthrosis of the proximal tibia: a case report.

Frontiers in pediatrics
2026

Nordic Society of Paediatric Haematology and Oncology (NOPHO) Radiotherapy Working Group consensus guidelines on radiotherapy for paediatric low-grade gliomas.

Acta oncologica (Stockholm, Sweden)
2026

Oral findings and oral health-related quality of life in children with neurofibromatosis type 1: a case-control study.

BMC oral health
2026

From diagnosis to daily life: A comparative pilot study on healthcare access and challenges for neurofibromatosis type 1 in public systems of Brazil and Portugal.

Clinics (Sao Paulo, Brazil)
2026

Neurofibromin 1 (NF1) Splicing Mutation c.61-2A>G: From Aberrant mRNA Processing to Therapeutic Implications In Silico.

International journal of molecular sciences
2026

Age-Specific ADHD and Internalizing/Externalizing Comorbidity in Children with Neurofibromatosis Type 1: A Multi-Site Study.

Cancers
2026

Diagnosis, treatment management, and challenges in neurofibromatosis type 1: a case report with mixed features.

Annals of medicine and surgery (2012)
2025

Laryngeal neurofibroma: case report and review of the literature.

Frontiers in oncology
2026

Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research.

Clinical cancer research : an official journal of the American Association for Cancer Research
2026

Sleep-Wake Dysregulation and Altered Melatonin in Neurofibromatosis Type 1.

Sleep
2026

Impaired Bone Healing and Fracture Complications during Limb Lengthening in a Neurofibromatosis Type 1 Patient Receiving Selumetinib: Case Report and Literature Review.

Journal of orthopaedic case reports
2026

Unilateral Yasunari Nodule-Like Appearance in a Patient Without Neurofibromatosis Type 1.

European journal of case reports in internal medicine
2026

A Multi-parametric MRI and Machine Learning Study of Cerebellar Structure in Youth with Neurofibromatosis Type 1.

Cerebellum (London, England)
2026

Molecular convergence enables precision medicine for pediatric low grade gliomas.

Discover oncology
2026

Hepatic plexiform neurofibroma a rare manifestation of neurofibromatosis type 1: A case report and literature review.

Radiology case reports
2026

Early onset scoliosis in syndromic and neuromuscular disorders: A multidisciplinary approach.

Journal of clinical orthopaedics and trauma
2026

Sciatic Schwannoma in a Patient with Neurofibromatosis Type 1: A Report of a Minimally Invasive Surgical Technique and Review of the Literature.

Cureus
2026

Diffusely enlarged extraocular muscles in an infant with neurofibromatosis type 1.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2026

Neurofibromatosis type 1 plexiform neurofibromas: Integrating treatment across pediatric and adult populations.

Neuro-oncology
2026

Breast cancer risk in women with neurofibromatosis type 1: a register-based cohort study from Denmark and Sweden.

Breast (Edinburgh, Scotland)
2026

Phenotypic Spectrum of Neurofibromatosis Type 1 Patients in India and Low Prevalence of Microdeletions in NF1 Gene.

American journal of medical genetics. Part A
2025

[Neurofibromatosis 1-related tumors in pediatric patients].

Problemy endokrinologii
2026

Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards.

Journal of translational medicine
2026

Utilizing optical coherence tomography and machine learning to identify vision abnormalities in pediatric neurofibromatosis type 1 patients.

Scientific reports
2026

Bladder Fetal Rhabdomyoma Coexisting with Neurofibromatosis Type 1: A Differential Diagnostic Challenge.

Indian journal of pediatrics
2026

Neurofibromatosis type I -related severe aplastic anemia: an unusual association with a complicated bone marrow transplantation course.

Annals of hematology
2026

Disrupted Frontoparietal Dynamics in Neurofibromatosis Type 1: Reduced Sensitivity and Atypical Modulation During Working Memory.

Human brain mapping
2026

Variant Resolution Through RNA Testing and Affected Tissue Analysis in the Neurofibromatoses: A Case Series.

Neurology. Genetics
2026

Small bowel obstruction from jejunal gastrointestinal stromal tumour in a young adult with neurofibromatosis type 10: a case report.

Journal of surgical case reports
2025

Safe cystoperitoneal shunting of thoracic meningocele in a patient with neurofibromatosis type 1.

Surgical neurology international
2025

Internal carotid artery sympathetic plexus neurofibroma - A case report.

Surgical neurology international
2025

Plexiform Neurofibroma of the Vulva in a Patient With Neurofibromatosis Type 1.

Cureus
2026

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium.

European journal of human genetics : EJHG
2026

Cutting Balloon Angioplasty for Resistant Pediatric Renal Artery Stenosis: A Single Institutional Experience.

Journal of vascular and interventional radiology : JVIR
2026

Corneal confocal microscopy as a paraclinical test in neurodegenerative disease: a scoping review.

The British journal of ophthalmology
2025

Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.

Cureus
2026

Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.

Journal of clinical medicine
2026

Small Bowel Gastrointestinal Stromal Tumors: A 15-Year Cohort Study Focusing on Jejuno-Ileal Site-Specific Outcomes and Prognostic Factors.

Cancers
2025

Caffeine May Delay the Radiation-Induced Nucleoshuttling of the ATM Kinase and Reduce the Recognition of the DNA Double-Strand Breaks in Human Cells.

Biomolecules
2026

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2026

FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.

Acta neuropathologica
2026

Metachronous Pheochromocytoma and Cholangiocarcinoma in a patient with Neurofibromatosis type 1: a case report.

Oxford medical case reports
2026

Healthcare utilization patterns and costs related to neurofibromatosis 1 in Ontario, Canada.

Orphanet journal of rare diseases
2025

Subsequent primary and secondary neoplasms in childhood cancer survivors.

Polish journal of radiology
2026

Inhibition of Cxcr4 chemokine receptor signaling improves habituation learning in a zebrafish model of neurofibromatosis.

Disease models &amp; mechanisms
2026

HMGB1 affects the progression of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors through E2F2.

Cancer cell international
2026

Clinical and Humanistic Burden Among Adults with Neurofibromatosis Type 1 and Symptomatic Plexiform Neurofibroma in the United States.

Neurology and therapy
2026

[A man with axillary and inguinal freckling, café-au-lait spots, and cutaneous nodules].

Nederlands tijdschrift voor geneeskunde
2026

Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study.

Cancer
2025

(Not) "just your nature". Diagnostic journeys of adults with neurofibromatosis type 1 in Poland.

Frontiers in genetics
2026

Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.

PloS one
2026

Surgical treatment for neurofibromatosis type 1-related dystrophic scoliosis in children aged 8 to 11: traditional growing rod or posterior spinal fusion?

BMC surgery
2026

Asthma-mediated control of optic glioma growth via T cell-microglia interactions: A mathematical model.

NPJ systems biology and applications
2026

Unraveling cardiac anomalies in pediatric neurofibromatosis type 1: insights and implications.

European journal of pediatrics
2026

Neurofibromatosis Type 1 in Ecuador: genotype-phenotype correlations from a case series.

Medwave
2026

Microenvironmental TGF-β is an early driver of NF1-associated tumor formation.

Cell reports
2026

Genetic tumor syndromes in female cancer: insights into inherited cancer predisposition and clinical implications.

Archives of gynecology and obstetrics
2026

Prevalence and management of lower limb segmental overgrowth in patients with NF1: an observational study.

Orphanet journal of rare diseases
2026

Retroperitoneal malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1: a case report.

BMC surgery
2025

Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis.

Cureus
2026

Radiologic Approach to Cystic Lung Diseases: From Cyst Definition to Diagnosis.

Seminars in roentgenology
2025

Tips and Pitfalls of Surgical Techniques for Scoliotic Deformities in Neurofibromatosis Type 1.

Journal of clinical medicine
2026

NF1 with Multiple Cardiac Structural Abnormalities Leading to Cerebral Infarction.

Diagnostics (Basel, Switzerland)
2026

Breast cancer in a male with neurofibromatosis type 1.

Medicina clinica
2026

SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).

Clinical cancer research : an official journal of the American Association for Cancer Research
2026

Ask and you will find: the importance of measuring stigma due to cutaneous neurofibromas in neurofibromatosis type 1.

The British journal of dermatology
2026

Choroidal abnormalities in neurofibromatosis type 1.

Eye (London, England)
2025

Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.

Neuro-oncology advances
2025

Molecular and Clinical Profiles of Patients with RASopathies: Targeted Next-Generation Sequencing Panel Results and Identification of 14 Novel Disease-Causing Variants.

Molecular syndromology
2026

Midkine as a therapeutic node in NF1-driven neuro‑oncology: Biology, biomarkers, and translational strategies.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2026

Simultaneous reprogramming and gene correction to generate six iPSC lines and isogenic controls from individuals with neurofibromatosis type 1.

Stem cell research
2026

An intercostal artery aneurysm rupture in a patient with neurofibromatosis type 1-associated gastrointestinal stromal tumor during sunitinib therapy.

Clinical journal of gastroenterology
2026

Long-term Stable Unilateral Mandibular Deformity Associated With Ipsilateral Skull-base Soft-tissue Lesion and Degenerated Pterygoid Muscles in Neurofibromatosis Type 1.

Cancer diagnosis &amp; prognosis
2025

Trapped in Silence: Severe Catatonia From Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis in a Neurofibromatosis Type 1 Patient With Craniopharyngioma.

Cureus
2025

When the Skin Tells a Pulmonary Story: A Case of Neurofibromatosis Type 1-Associated Pulmonary Hypertension.

Cureus
2026

Adjuvant Radiation Therapy in Breast Cancer Patients With Neurofibromatosis Type 1: Safety and Long-Term Outcomes.

Advances in radiation oncology
2025

[Von Recklinghausen's disease revealed by a thoracic mass and pulmonary cystic lesions].

The Pan African medical journal
2026

Targeted therapies in optic pathway gliomas.

Cancer treatment reviews
2025

Malignant peripheral nerve sheath tumors in neurofibromatosis type 1 arise from distinct nodular lesions: A retrospective imaging analysis.

Neuro-oncology advances
2026

NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.

Neurology
2025

High-Resolution Nerve Ultrasound in Adults with NF1: An Accessible and Reproducible Imaging Tool for Plexiform Neurofibromas.

Diagnostics (Basel, Switzerland)
2025

The Pathogenesis of the Neurofibroma-to-Sarcoma Transition in Neurofibromatosis Type I: From Molecular Profiles to Diagnostic Applications.

Cancers
2026

Frequency and face validity of reported family history of cancer in first-degree relatives and genetic syndromes among children with cancer in Project:EveryChild: A report from the Children's Oncology Group.

Cancer
2026

MOIS-SAM2: Exemplar-based segment anything model 2 for multi-lesion interactive segmentation of neurofibromas in whole-body MRI.

Computers in biology and medicine
2026

Concurrent Juvenile Myelomonocytic Leukemia and Gliomas in Patients With Neurofibromatosis Type 1.

Pediatric blood &amp; cancer
2025

Genetic activation of ERK2 recapitulates core neurodevelopmental features of Rasopathy syndromes in mice.

bioRxiv : the preprint server for biology
2025

Non-Syndromic Ganglioneuromatosis of the Gallbladder, an Extremely Rare Condition: Case Report and Literature Review.

Reports (MDPI)
2025

Consensus on Malignant and Benign Tumors in Pediatric Patients with Neurofibromatosis Type 1: On Behalf of the Brazilian Society of Pediatric Oncology (SOBOPE).

Current oncology (Toronto, Ont.)
2026

Incidence of Bevacizumab-Associated Toxicity in Children With Low-Grade Glioma With and Without Neurofibromatosis Type 1.

Pediatric blood &amp; cancer
2025

Post-strabismus surgery endophthalmitis without evident scleral perforation due to Haemophilus influenzae in a pediatric patient with neurofibromatosis type 1.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2026

Clinical significance of thalamic FASI finding in neurofibromatosis type 1: Deepening the cognitive relevance with advanced approaches.

Clinical neurology and neurosurgery
2026

The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings.

Annales de dermatologie et de venereologie
2025

PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.

PLoS genetics
2025

Pathological and Immunohistochemical Features of Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomy Oblastic Differentiation (Malignant Triton Tumor) in the Context of the Malignant Peripheral Nerve Sheath Tumor Spectrum.

International journal of surgical pathology
2026

Phenotypic characterization of neurofibromatosis type 1 in a large Chinese cohort: A cross-sectional study.

JAAD international
2025

Protein domain-specific genotype-phenotype correlation study of neurofibromatosis type 1.

Scientific reports
2025

Pharmacological inhibition of RAS pathway alleviates spine deformity in a mouse model of neurofibromatosis type 1.

Bone research
2026

[Malignant peripheral nerve sheath tumor presenting with Pancoast syndrome in a ‍patient with neurofibromatosis type 1].

Rinsho shinkeigaku = Clinical neurology
2025

Clinical benefits of selumetinib in adults with neurofibromatosis type 1 - Authors' reply.

Lancet (London, England)
2025

Clinical benefits of selumetinib in adults with neurofibromatosis type 1.

Lancet (London, England)
2025

Malignant peripheral nerve sheath tumors: a report from children's oncology group study ARST0332.

Journal of the National Cancer Institute
2025

Neurofibromatosis Type 1: Genetic Mechanisms and Advances in Therapeutic Innovation.

Cancers
2025

Challenges and Progress for Treatment of Malignant Peripheral Nerve Sheath Tumors in the Context of Recent Successes for Sarcoma Therapy.

Cancers
2025

Genetic characterization of a Chinese cohort of suspected pediatric NF1 patients: a large-scale study using optimized whole-exome sequencing.

Journal of human genetics
2025

Fatal Triad of Subarachnoid Hemorrhage, Cervical Hematoma, and Upper Airway Obstruction in a Patient With Neurofibromatosis Type 1: A Case Report.

Critical care explorations
2025

Ruptured giant lateral thoracic meningocele associated with intracranial hypotension syndrome in neurofibromatosis type 1: case report with long-term follow-up.

Frontiers in oncology
2025

An Episcleral Lesion in a Patient With Neurofibromatosis Type 1.

Ophthalmic plastic and reconstructive surgery
2025

Exploring Optic Glioma and Type 1 Neurofibromatosis: A Literature Review of Case Reports.

Neuro-ophthalmology (Aeolus Press)
2025

Coexistence of ulcerative colitis and neurofibromatosis type 1: a case report and literature review.

Frontiers in medicine
2025

Attention skills, learning and academic abilities in children and adolescents with genetic disorders: a systematic review.

Frontiers in psychology
2026

The Efficacy of the iCanCope Mobile Application for Neurofibromatosis Type 1 (NF1): A Three-Arm Randomized Controlled Trial.

American journal of medical genetics. Part A
2025

Neurodevelopmental and Psychiatric Studies in Children and Adolescents With Neurofibromatosis Type I: A Comprehensive Scoping Review.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
2025

Diagnostic challenges of the neurofibroma-malignant peripheral nerve sheath tumor spectrum in neurofibromatosis type 1: illustrative case.

Journal of neurosurgery. Case lessons
2025

Optic Nerve Glioma, Plexiform Neurofibroma, and Secondary Glaucoma in a Child With a Rare NF1 Variant (p.Gln83Ter): A Case Report.

Cureus
2025

Bibliometric Analysis of Global Research on Cafe-Au-Lait Macules from 2000 to 2025: Development, Collaboration Patterns, and Emerging Trends.

Clinical, cosmetic and investigational dermatology
2024

[Ganglioneuroma of the Small Intestine Mimicking Crohn's Disease].

Acta gastroenterologica Latinoamericana
2025

Family Functioning, Anxiety, and Depressive Symptoms and Their Impact on Quality of Life in Children With Neurofibromatosis Type 1.

Journal of child neurology
2025

Malignant Peripheral Nerve Sheath Tumor Arising After Superficial Neurofibroma Excision: A Rare Sporadic Case in a Patient Without Neurofibromatosis Type 1.

Cureus
2025

Neurofibromatosis type 1-associated tumors in children.

The Turkish journal of pediatrics
2026

Radiological insights into orbital and periorbital plexiform neurofibromas in children with neurofibromatosis type 1.

Radiology case reports
2026

Cracking under pressure: Cognitive load influences performance in youth with NF1.

Journal of the International Neuropsychological Society : JINS
2025

Neurofibromatosis review with focus on rehabilitation intervention.

Current problems in pediatric and adolescent health care
2025

RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications.

Journal of neuropathology and experimental neurology
2025

Quantitative assessment of the corneal subbasal nerve plexus in children with neurofibromatosis type 1 and optic pathway glioma using in vivo confocal microscopy.

Scientific reports
2025

Prevalence of optic pathway glioma in NF1: a systematic review and meta-analysis focused on MRI surveillance.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2025

Academic Achievement of Children and Adolescents with Neurofibromatosis Type 1: A Systematic Review and Meta-Analysis.

Neuropsychology review
2025

High Allelic Heterogeneity in Kazakhstani Patients with Neurofibromatosis Type 1: Results from the First Molecular Study.

Genes
2025

Clinical characteristics and healthcare burden of neurofibromatosis type 1 in Saudi Arabia: a single centre experience.

Hereditary cancer in clinical practice
2025

Neurofibromatosis Type 1 and the Search for Effective Tumor Therapies Using High-Throughput Drug Screening.

Current oncology (Toronto, Ont.)
2026

Retrospective Analysis of Pediatric Optic Pathway Gliomas: Impact of NF1 Status on Visual and Structural Outcomes.

American journal of ophthalmology
2026

Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: development, validation and severity strata of the cNF-PUSH-D.

The British journal of dermatology
2026

Conservative Management of Spontaneous Posterior Mediastinal Intercostal Artery Hemorrhage: A Case Report and Literature Review.

The Journal of emergency medicine
2026

Preimplantation genetic testing for neurofibromatosis type 1: molecular genetic aspects and impact on reproductive counseling.

Human reproduction (Oxford, England)
2025

[Identification of two novel NF1 mutations and genotype-phenotype analysis in patients with neurofibromatosis type 1].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
2026

Genotype-first assessment of presentation and penetrance of neurofibromatosis type 1, autosomal dominant polycystic kidney disease, and Marfan syndrome within the All of Us research program cohort.

Genetics in medicine : official journal of the American College of Medical Genetics
2025

Clinical challenges of cancer predisposition syndromes with pediatric central nervous system tumors: a single-center study.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
Ver todos os 4.300 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Associação brasileira dedicada a Doenças raras (geral).

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Neurofibromatose tipo 1 e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

A neurofibromatose tipo 1 é uma doença genética neurocutânea caracterizada por manchas café com leite, sardas em dobras da pele e formação de neurofibromas ao longo dos nervos. Ela se manifesta tipicamente nos primeiros anos de vida e pode apresentar grande variedade de sintomas entre os pacientes.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 8 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:636
    Orphanet
  2. GARD:7866
    GARD (NIH)
  3. Q847605
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Neurofibromatose tipo 1. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/neurofibromatose-tipo-1

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Neurofibromatose tipo 1

ORPHA:636 · MONDO:0018975
🇧🇷 Brasil SUS
SIGTAP
5 procedimentos
Geral
Prevalência
1-5 / 10 000
Herança
Autosomal dominant
CID-10
Q85.0 · Neurofibromatose (não-maligna)
CID-11
Ensaios
35 ativos
Início
Infancy, Neonatal
Prevalência
21.0 (United Kingdom)
MedGen
UMLS
C0027832
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Genética mendeliana
fonte: OMIM
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Medicamentos aprovados FDA
fonte: FDA OpenFDA
Rara